The study of Noxxon in metastatic pancreatic cancer and metastatic colorectal cancer, conducted within the framework of a collaboration agreement with Merck & Co/MSD, will be held in a cancer center, a world renowned
Download the free guide
Boost your gains
Berlin, Germany, on may 16, 2017 – NOXXON Pharma N. V. (Alternext Paris : ALNOX), a biopharmaceutical company developing mainly cancer treatments targeting the tumor microenvironment, today announced the signing of an agreement with the National Center for Tumor Diseases (NCT) Heidelberg, according to which the latter will conduct a study evaluating its product candidate lighthouse NOX-A12 is associated with the Keytruda® (pembrolizumab) in metastatic pancreatic cancer and metastatic colorectal cancer. Some preclinical studies have shown that NOX-A12 was able to make the area surrounding the tumor in a model tumor, called the tumor microenvironment, more accessible to the immune system. The researchers believe that the ability of many tumors using the tumor microenvironment to hide from the immune system contributes to the insensitivity of some tumors to inhibitors of the checkpoint, such as Keytruda.
Download the free guide
Boost your gains
